Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$1.71 USD
-0.05 (-2.84%)
Updated Aug 27, 2024 04:00 PM ET
Pre-Market: $1.71 0.00 (0.00%) 9:14 AM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.71 USD
-0.05 (-2.84%)
Updated Aug 27, 2024 04:00 PM ET
Pre-Market: $1.71 0.00 (0.00%) 9:14 AM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
Zacks News
Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year
by Zacks Equity Research
Esperion (ESPR) reports a narrower-than-expected loss for the second quarter of 2024. Revenues beat estimates. Sales rise year over year owing to higher collaboration revenues.
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 66.67% and 42.27%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 14.29% and 6.75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Verve Therapeutics (VERV) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Verve Therapeutics (VERV) delivered earnings and revenue surprises of 13.24% and 27.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of -100% and 2.51%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength in Kidney Care Likely to Aid DaVita's (DVA) Q2 Earnings
by Zacks Equity Research
Improvement in RPT and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the second quarter.
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Product Demand Likely to Aid Organon's (OGN) Q2 Earnings
by Zacks Equity Research
Continued solid uptake of Organon's (OGN) products is expected to have driven second-quarter revenues.
Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q2 results are likely to gain from growth in Emerging Markets and Europe and expansion of business activities in Japan, offset by declines in North America.
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 39.13% and 6.41%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
by Zacks Equity Research
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk
by Zacks Equity Research
Esperion's (ESPR) Nilemdo & Nustendi get the European Commission's nod for label expansion based on data from the CLEAR Outcomes study.
Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
by Zacks Equity Research
Esperion's (ESPR) first-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.
Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 525% and 159.32%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
by Zacks Equity Research
United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics are part of the Zacks Industry Outlook article.
5 Small Drug Stocks to Buy From a Rebounding Industry
by Kinjel Shah
Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.
Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues
by Zacks Equity Research
Esperion's (ESPR) fourth-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.
Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 5.66% and 20.16%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical (DERM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
When Journey Medical (DERM) reports fourth-quarter 2023 results, investors will likely focus on the top and bottom-line numbers.
Viatris (VTRS) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
Viatris' (VTRS) Q4 results are likely to gain from momentum in its branded and generic businesses.